Skip to content

Evaluation the efficacy of a syrup of Echium amoenum-Melissa officinalis in treatment of adolescents with Obsessive-Compulsive Disorder

Evaluation the efficacy of a syrup of Echium amoenum-Melissa officinalis in treatment of adolescents with Obsessive-Compulsive Disorder

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20191127045521N1
Enrollment
40
Registered
2019-12-05
Start date
2019-12-22
Completion date
Unknown
Last updated
2021-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obsessive-Compulsive Disorder. Mixed obsessional thoughts and acts

Interventions

Intervention 1: Intervention group will receive a Echium amoenum-Melissa officinalis syrup, 0.3 milliliter per kilogram of body weight and 50 mg Fluvoxamine tablets daily for 8 weeks. Intervention 2:

Sponsors

Mashhad University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
13 Years to 17 Years

Inclusion criteria

Inclusion criteria: Obsessive-Compulsive Disorder with a diagnosis of pediatric psychiatry according to DSM-5 criteria Ages 13 to 17 years

Exclusion criteria

Exclusion criteria: Psychosis Bipolar disorder Catatonic symptoms Drug abuse Severe or debilitating illnesses Phenobarbital consumption Oxazepam consumption Sedative drugs consumption

Design outcomes

Primary

MeasureTime frame
Obsessive score on children's Yale-Brown Obsessive Compulsive questionnaire. Timepoint: pretest, 4 weeks after beginning, post-test (at the end of 8 weeks). Method of measurement: children's Yale-Brown Obsessive Compulsive questionnaire.

Secondary

MeasureTime frame
Quality of life score. Timepoint: pretest, post-test (at the end of 8 weeks). Method of measurement: The World Health Organization Quality of Life Questionnaire.;Anxiety score. Timepoint: pretest, 4 weeks after beginning, post-test (at the end of 8 weeks). Method of measurement: Spence Children's Anxiety Questionnaire.;Depression score. Timepoint: pretest, 4 weeks after beginning, post-test (at the end of 8 weeks). Method of measurement: Maria Kovas Depression Questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Hosseini Abrishami

Mashhad University of Medical Sciences

Hoseiniam951@mums.ac.ir+98 51 3884 8931

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 12, 2026